Search Results - "Riedel, K‐D"

Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients by Ngaimisi, E, Mugusi, S, Minzi, O M, Sasi, P, Riedel, K‐D, Suda, A, Ueda, N, Janabi, M, Mugusi, F, Haefeli, W E, Burhenne, J, Aklillu, E

“…We investigated the influence of gender and pharmacogenetic variations on long‐term efavirenz autoinduction and disposition among patients with HIV in Tanzania…”
Get full text

Effect of Rifampicin and CYP2B6 Genotype on Long‐Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis by Ngaimisi, E, Mugusi, S, Minzi, O, Sasi, P, Riedel, K‐D, Suda, A, Ueda, N, Janabi, M, Mugusi, F, Haefeli, W E, Bertilsson, L, Burhenne, J, Aklillu, E

“…We performed a prospective comparative study to examine, from a pharmacogenetics perspective, the effect of rifampicin (RIF) on long‐term efavirenz (EFV)…”
Get full text

Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy by Katzenmaier, S, Markert, C, Riedel, K-D, Burhenne, J, Haefeli, W E, Mikus, G

“…We established a new limited sampling strategy to assess CYP3A activity and evaluated the time course of reversible (voriconazole) and irreversible (ritonavir)…”
Get full text

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients by Habtewold, A, Amogne, W, Makonnen, E, Yimer, G, Nylén, H, Riedel, K-D, Aderaye, G, Bertilsson, L, Burhenne, J, Diczfalusy, U, Aklillu, E

“…We investigated the effects of pharmacogenetic variations and efavirenz pharmacokinetics on inter-individual differences in the extent of CYP3A induction by…”
Get full text

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment by Ngaimisi, E, Minzi, O, Mugusi, S, Sasi, P, Riedel, K-D, Suda, A, Ueda, N, Bakari, M, Janabi, M, Mugusi, F, Bertilsson, L, Burhenne, J, Aklillu, E, Diczfalusy, U

“…To assess the effect of the major efavirenz metabolizing enzyme (CYP2B6) genotype and the effects of rifampicin co-treatment on induction of CYP3A by…”
Get full text

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients by Habtewold, Abiy, Amogne, Wondwossen, Makonnen, Eyasu, Yimer, Getnet, Riedel, Klaus-Dieter, Ueda, Nobuhisa, Worku, Alemayehu, Haefeli, Walter Emil, Lindquist, Lars, Aderaye, Getachew, Burhenne, Jürgen, Aklillu, Eleni

“…Objectives We investigated the long-term effect of efavirenz autoinduction on its plasma/peripheral blood mononuclear cell (PBMC) exposure and the CD4 count,…”
Get full text

Steady-state pharmacokinetics and metabolism of voriconazole in patients by Geist, Marcus J P, Egerer, Gerlinde, Burhenne, Jürgen, Riedel, Klaus-Dieter, Weiss, Johanna, Mikus, Gerd

“…Voriconazole exhibits non-linear pharmacokinetics in adults and is said to be mainly metabolized by CYP2C19 and CYP3A4 to voriconazole-N-oxide. The aim of this…”
Get full text

Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid by Rengelshausen, J, Göggelmann, C, Burhenne, J, Riedel, K D, Mikus, G, Walter-Sack, I, Haefeli, W E

“…Urinary caffeine metabolic ratios used to quantify the activity of numerous drug-metabolizing enzymes are an established component of cocktail approaches for…”
Get full text

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations by Ngaimisi, Eliford, Habtewold, Abiy, Minzi, Omary, Makonnen, Eyasu, Mugusi, Sabina, Amogne, Wondwossen, Yimer, Getnet, Riedel, Klaus-Dieter, Janabi, Mohammed, Aderaye, Getachew, Mugusi, Ferdinand, Bertilsson, Leif, Aklillu, Eleni, Burhenne, Juergen

“…We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in…”
Get full text

High beta-glucan oat bran and oat gum reduce postprandial blood glucose and insulin in subjects with and without type 2 diabetes by Braaten, J T, Scott, F W, Wood, P J, Riedel, K D, Wolynetz, M S, Brulé, D, Collins, M W

“…The aim of the current study was to characterize the effects of isolated and native sources of beta-glucan, oat gum, and oat bran, respectively, when…”
Get more information

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients by Yimer, Getnet, Ueda, Nobuhisa, Habtewold, Abiy, Amogne, Wondwossen, Suda, Akira, Riedel, Klaus-Dieter, Burhenne, Jürgen, Aderaye, Getachew, Lindquist, Lars, Makonnen, Eyasu, Aklillu, Eleni

“…Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercular drug induced…”
Get full text

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4 -hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment by Ngaimisi, E., Minzi, O., Mugusi, S., Sasi, P., Riedel, K.- D., Suda, A., Ueda, N., Bakari, M., Janabi, M., Mugusi, F., Bertilsson, L., Burhenne, J., Aklillu, E., Diczfalusy, U.

“…To assess the effect of the major efavirenz metabolizing enzyme (CYP2B6) genotype and the effects of rifampicin co-treatment on induction of CYP3A by…”
Get full text

Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania by Mugusi, Sabina, Ngaimisi, Eliford, Janabi, Mohamed, Minzi, Omary, Bakari, Muhammad, Riedel, Klaus-Dieter, Burhenne, Juergen, Lindquist, Lars, Mugusi, Ferdinand, Sandstrom, Eric, Aklillu, Eleni

“…To investigate the timing, incidence, clinical presentation, pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug…”
Get full text

The Pharmacokinetics of Extended-Release Formulations of Calcium Antagonists and of Amlodipine in Subjects with Different Gastrointestinal Transit Times by Zimmermann, Torsten, Laufen, Heinrich, Yeates, Rodney, Scharpf, Friedrich, Riedel, Klaus-Dieter, Schumacher, Tilo

“…The influence of gastrointestinal (GI) transit times on the pharmacokinetics (PK) of three calcium channel blockers (CCBs), recommended for once‐daily dosing,…”
Get full text

Oat gum lowers glucose and insulin after an oral glucose load by Braaten, JT, Wood, PJ, Scott, FW, Riedel, KD, Poste, LM, Collins, MW

“…Foods containing soluble dietary fibers delay glucose absorption and lower postprandial plasma glucose. This effect of oat bran has been attributed to oat gum…”
Get full text

Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria by RENGELSHAUSEN, Jens, BURHENNE, Jürgen, WALTER-SACK, Ingeborg, FRÖHLICH, Margit, TAYROUZ, Yorki, SHIO KUMAR SINGH, RIEDEL, Klaus-Dieter, MÜLLER, Olaf, HOPPE-TICHY, Torsten, HAEFELI, Walter E, MIKUS, Gerd

“…The combination of chloroquine and methylene blue is potentially effective for the treatment of chloroquine-resistant malaria caused by Plasmodium falciparum…”
Get full text

The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole by Zimmermann, T, Yeates, R A, Riedel, K D, Lach, P, Laufen, H

“…AIDS patients may have achlorhydria, a condition that could result in drug malabsorption, especially of antifungals. The effect of a reduction in the…”
Get more information

Effect of dose and modification of viscous properties of oat gum on plasma glucose and insulin following an oral glucose load by J.Wood, Peter, Braaten, Jan T., Scott, Fraser W., Riedel, K. Doreen, Wolynetz, Mark S., Collins, Maurice W.

“…An extract from oats known as oat gum (OG) is composed mainly of the polysaccharide (1→3) (1→4)-β-D-glucan, which is highly viscous in aqueous solution…”
Get full text

High-performance thin-layer chromatographic assay for the routine determination of piroxicam in plasma, urine and tissue by Riedel, K D, Laufen, H

Get more information

Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction by Rengelshausen, Jens, Göggelmann, Christoph, Burhenne, Jürgen, Riedel, Klaus‐Dieter, Ludwig, Jochen, Weiss, Johanna, Mikus, Gerd, Walter‐Sack, Ingeborg, Haefeli, Walter E.

“…Aims  A clinically important interaction between the cardiac glycoside digoxin and the antibiotic clarithromycin has been suggested in earlier reports. The aim…”
Get full text